Small cell lung cancer

Mayo Clinic Proceedings

Volumn 83, Issue 3, 2008, Pages 355-367

  Sher, Taimur ^a   Dy, Grace K ^a   Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 263; AMRUBICIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; ISOSORBIDE; METHOTREXATE; NAVELBINE; OBLIMERSEN; PACLITAXEL; PEMETREXED; PICOPLATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINCRISTINE; ZD 2171;

ASIAN; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CEREBELLUM DEGENERATION; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; EATON LAMBERT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; JAPAN; LUNG CARCINOMA; LUNG INFILTRATE; LUNG SMALL CELL CANCER; LUNG TOXICITY; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PARANEOPLASTIC SYNDROME; PATIENT COMPLIANCE; PNEUMONIA; REVIEW;

EID: 41549084663     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.3.355     Document Type: Article

References (133)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007. http://www.cancer.org/downloads/STT /CAFF2007PWSecured.pdf. Accessed February 4, 2008.
2. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract 7082]. J Clin Oncol. 2006; 24(18S)(suppl):384S.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-4544.
4. Thompson S, Pearson MG. Changing patterns of lung cancer histology with age and gender. Thorax. 1998;53(suppl 4):A10.
5. Kmietowicz Z. Women at double risk of small cell lung cancer. BMJ. 1998;317(12):1614.
6. Cartman ML, Muers MF. Rising incidence of SCLC in young women [letter]. Thorax. 1999;54(7):656.
7. Guinee DG Jr, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol. 1994;102(4):406-414.
8. Kumar V, Abbas AK, Fausto N, eds. Robins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier Inc; 2005:757-768.
9. Otterson G, Lin A, Kay F. Genetic etiology of lung cancer. Oncology (Williston Park). 1992;6(9):97-104.
10. Graziano SL, Pfeifer AM, Testa JR, et al. Involvement of the RAF 1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer. Genes Chromosomes Cancer. 1991;3(4):283-293.
11. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the protooncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer. 1993;67(1):37-46.
12. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272-6281.
13. Bharti A, Ma PC, Maulik G, et al. Haptoglobin ?-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004;24(2C):1031-1038.
14. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002;8(2):620-627.
15. Maulik G, Madhiwala P, Brooks S, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002;6(4):539-553.
16. Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 6;97(3):368-377. Epub 2007 Jul 31.
17. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res. 1992;52(11):3089-3093.
18. Damstrup L, Rude Voldborg B, Spang-Thomsen M, Brünner N, Skovgaard Poulsen H. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer. 1998;78(5):631-640.
19. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987;84(20):7159-7163.
20. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 1992;7(9):1859-1866.
21. Micke P, Hengstler JG, Ros R, et al. c-erbB2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer. 2001;92(4):474-479.
22. Molina JR, Adjei AA. The Ras/Raf/MAPK Pathway. J Thorac Oncol. 2006;1(1):7-9.
23. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 1995;15(2):503-505.
24. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177(2):135-138.
25. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. Summer 1994;4(2):71-79.
26. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 2000;6(9):1029-1035.
27. Wistuba L, Gadzar AF, Minna JD. Molecular genetics of small cell lung carcinoma, Semin Oncol. 2001;28(2)(suppl 4):3-13.
28. Midgley CA, Desterro JM, Saville MK, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 2000;19(19):2312-2323.
29. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994; 54(9):2287-2291.
30. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006;25(1):35-43.
31. Tang X, Liu D, Shishodia S, et al. Nuclear factor-κB (NF-κ?B) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006; 107(11):2637-2646.
32. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Jan 1;173(1):16-22. Epub 2005 Sep 1.
33. Wu T, Hu Y, Chen C, et al. Passive smoking, metabolic gene polymorphisms, and infant birth weight in a prospective cohort study of Chinese women. Am J Epidemiol. 2007 Aug 1;166(3):313-322. Epub 2007 May 25.
34. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004 Sep;75(3):460-474. Epub 2004 Jul 21.
35. Dally H, Edler L, Jager B, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13(10):607-618.
36. Dally H, Gassner K, Jager B, et al. Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102(5): 530-535.
37. Patel AM, Davila DG, Peters SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc. 1993;68(3):278-287.
38. Johnson DH, Hainsworth JD, Greco FA. Pancoast's syndrome and small cell lung cancer. Chest. 1982;82(5):602-606.
39. Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol. 1978;5(3):272-279.
40. Pass HI, Carbone D, Johnson D, eds. Lung Cancer: Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:78.
41. Voltz R, Carpentier AF, Rosenfeld MR, Posner JB, Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve. 1999;22(1):119-122.
42. Carpentier AF, Voltz R, DesChamps T, Posner JB, Dalmau J, Rosenfeld MR. Absence of HuD gene mutations in the paraneoplastic small cell lung cancer tissue. Neurology. 1998;50(6):1919.
43. Hamrick RM III, Murgo AJ. Lactate dehydrogenase values and bone scans as predictors of bone marrow involvement in small cell lung cancer. Arch Intern Med. 1987;147(6):1070-1071.
44. Kristjansen PE, Osterlind K, Hansen M. Detection of bone marrow relapse in patients with small cell carcinoma of the lung. Cancer. 1986; 58(11):2538-2541.
45. Campbell LJ, Van der Weyden MB. Hematological, biochemical and bone scan findings in patients with marrow carcinoma. Pathology. 1991;23(3): 198-201.
46. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and the LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986;12(5):771-777.
47. Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988;15(3):278-299.
48. Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol. 1986;4(9):1307-1313.
49. Paesmans M, Sculier JP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523-533.
50. Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer. 2002;4(2):87-94.
51. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? a meta-analysis. J Clin Oncol. 1992;10(6):890-895.
52. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618-1624.
53. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106(6 suppl):320S-323S.
54. Johnson DH, Einhorn LH, Mandelbaum I, Williams SD, Greco FA. Postchemotherapy resection of residual tumor in limited stage small cell lung cancer. Chest. 1987;92(2):241-246.
55. Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical treatment for limited small-cell lung cancer: the University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg. 1991;101(3):385-393.
56. Shepherd FA, Ginsberg R, Patterson GA, et al. Is there ever a role for salvage operations in limited small-cell lung cancer? J Thorac Cardiovasc Surg. 1991;101(2):196-200.
57. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989; 59(4):578-583.
58. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3(11):1471-1477.
59. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited stage small-cell lung cancer. J Clin Oncol. 1988;6(3):451-456.
60. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409-422.
61. Sundstrom S, Bremnes RM, Kaasa S, et al, Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20(24):4665-4672.
62. Wolf M, Havemann K, Drings P, et al. Alternating chemotherapy with doxorubicin, ifosfamide, and vincristine plus cisplatin and etoposide versus doxorubicin, ifosfamide, and vincristine plus carboplatin and etoposide in small cell lung cancer. In: Bunn PA Jr, Canette R, Ozols RF, et al, eds. Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA: Saunders; 1990:283-294.
63. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 1998;16(2):642-650.
64. Crivellari G, Monfardini S, Stragliotto S, Marino D, Aversa SM. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist. 2007;12(1):79-89.
65. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9(3):499-508.
66. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993;329(25):1848-1852.
67. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12(10):2022-2034.
68. Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol. 1987;5(12):1864-1873.
69. Fetscher S, Brugger W, Engelhardt R, et al. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-call lung cancer: a mature follow-up report. Ann Oncol. 1999;10(5):561-567.
70. Roof KS, Fidias P, Lynch TJ, Ancukiewicz M, Choi NC. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57(3):701-708.
71. Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited-stage small-cell carcinoma: an update. Int J Radiat Oncol Biol Phys. 1989;17(2):307-310.
72. Miller KL, Marks LB, Sibley GS, et al. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiation Oncol Biol Phys. 2003;56(2):355-359.
73. Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol. 1997;15(8): 2840-2849.
74. Takada M, Fukuoka M, Kawahara M, et al, Japan Clinical Oncology Group. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054-3060.
75. Okawara G, Gagliardi A, Evans WK, et al. Cancer Care Ontario: the role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small cell lung cancer. Practice Guideline Report 7-13-3, 1/03 update. http://www.cancercare.on.ca/pdf/pebc7-13-3s.pdf. Accessed February 12, 2008.
76. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer [published correction appears in J Clin Oncol. 2005;23(1):248]. J Clin Oncol. 2004;22(23):4837-4845.
77. Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265-271.
78. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681-2691.
79. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999;17(6):1794-1801.
80. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8-15.
81. Skarlos DV, Samantas E, Kosmidis P, et al, Lung Cancer Study Group. Randomized comparison of etoposide-cisplatinum vs. etoposide-carboplatin and irradiation in small-cell lung cancer: a Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5(7):601-607.
82. Noda K, Nishiwaki Y, Kawahara M, et al, Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85-91.
83. Hanna NH, Einhorn L, Sandler A, et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC) [abstract LBA7004]. J Clin Oncol. 2005;23(16S)(suppl).
84. Lara P Jr, Redman M, Lenz H, et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124 [abstract 7524]. J Clin Oncol. 2007;25(18S) (suppl).
85. Hermes A, Bergman B, Bremnes R, et al. Randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study [abstract 7523]. J Clin Oncol. 2007;25(18S)(suppl).
86. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409-1411.
87. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-667.
88. Raju RN, Neubauer MA, Smith DA, et al. Pemetrexed (P) in relapsed small cell lung cancer (SCLC): preliminary results of a phase II trial [abstract 7716]. J Clin Oncol. 2007;25(18S)(suppl).
89. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer [published correction appears in J Clin Oncol. 2007;25(1):167]. J Clin Oncol. 2006;24(30):4840-4847.
90. Kristjansen PE, Hansen HH. Prophylactic cranial irradiation in small cell lung cancer - an update. Lung Cancer. 1995;12(suppl 3):S23-S40.
91. Harris DT. Prophylactic cranial irradiation in small-cell lung cancer. Semin Oncol. 1993;20(4):338-350.
92. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183-190.
93. Auperin A, Arriagada R, Pignon JP, et al, Prophylactic Cranial Irradiation Overview Collaboration Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476-484.
94. Fonseca R, O'Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc. 1999;74(5):461-465.
95. Slotman B, Faivre-Finn C, Kramer G, et al, EORTC Radiation Oncology Group, Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664-672.
96. Bentzion D, Lipatov O, Polyakov I, Mackintosh R, Eckhardt J, Breitz H. A phase II study of picoplatin (pico) as second-line therapy for patients (pts) with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum (plat)-containing chemotherapy [abstract 7722]. J Clin Oncol. 2007;25(18S)(suppl).
97. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs. 1997;15(3):219-225.
98. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res. 1989;80(1):69-76.
99. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res. 1989;80(1):77-82.
100. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 1998; 16(2)121-128.
101. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24(34):5448-5453.
102. Zakowski MF, Ladanyi M, Kris MG, Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked [letter]. N Engl J Med. 2006; 355(2):213-215.
103. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer [letter]. Ann Oncol. 2006 Jun;17(6):1028-1029. Epub 2005 Dec 15.
104. Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 2007 Nov;98(11):1714-1719. Epub 2007 Sep 2.
105. Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of nonsmall cell and small cell lung cancer with the same EGFR mutation. Lung Cancer. 2007 Dec;58(3):411-413. Epub 2007 Jun 29.
106. Johnson BE, Heymach JV. Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res. 2004;10(12, pt 2):4254s-4257s.
107. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6(8):1353-1362.
108. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995;55(22):5302-5309.
109. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol. 2004;15(8):1187-1193.
110. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6(8):3319-3326.
111. Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9(16, pt 1):5880-5887.
112. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005 Nov;16(11):1811-1816. Epub 2005 Aug 8.
113. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol. 2007;2(9):854-861.
114. Schneider BJ, Gadgeel S, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC) [abstract 17089]. J Clin Oncol. 2006;24(18S)(suppl).
115. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol. 1999;181(2):251-257.
116. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U . Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 1997;89(14):1027-1036.
117. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer. 1998;78(8):1035-1042.
118. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005 Jun 2;435(7042):677-681. Epub 2005 May 15.
119. Lara PN Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006;1(9):996-1001.
120. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65(18):8423-8432.
121. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hoffmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res. 2005;11(4):1563-1571.
122. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007;2(11):1036-1041.
123. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002;20(22):4434-4439.
124. Sandler A, Szwaric S, Dowlati A, Moore DF Jr, Schiller JH. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group [abstract 7564]. J Clin Oncol. 2007;25(18S)(suppl).
125. Ready N, Dudek AZ, Wang XF, Graziano S, Green MR, Vokes EE. CALGB 30306: a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ESSCLC) [abstract 7563]. J Clin Oncol. 2007;25(18S)(suppl).
126. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25(27):4278-4284.
127. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082-4085.
128. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebocontrolled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007;25(25):3945-3951.
129. Lee S-M, Woll PJ, James LE, et al. A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC) [abstract PRS-04]. J Thorac Oncol. 2007;2(8)(suppl 4):S306-S307.
130. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited disease small cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; SILVA study). J Clin Oncol. 2005; 23(28):6854-6864.
131. Fossella F, McCann J, Tolcher A, et al. Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma [abstract 7159]. J Clin Oncol. 2005;23(16S)(suppl).
132. McCann J, Fossella FV, Villalona-Calero AW, et al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma [abstract 18084]. J Clin Oncol. 2007; 25(18S)(suppl).
133. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12(3, pt 1):878-887.